540211
PTP Inhibitor IV
The PTP Inhibitor IV, also referenced under CAS 329317-98-8, controls the biological activity of PTP. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.
登录查看公司和协议定价
所有图片(1)
别名:
PTP Inhibitor IV, bis(4-Trifluoromethylsulfonamidophenyl)-1,4-diisopropylbenzene, Protein Tyrosine Phosphatase Inhibitor IV
经验公式（希尔记法）:
C26H26F6N2O4S2
推荐产品
质量水平
检测方案
≥95% (HPLC)
形式
solid
制造商/商品名称
Calbiochem®
储存条件
OK to freeze
protect from light
颜色
white to off-white
溶解性
DMSO: 10 mg/mL
acetonitrile: soluble
运输
ambient
储存温度
2-8°C
一般描述
An uncharged, 1,4-di-substituted, phenyl-linked bis-trifluoromethylsulfonamido (TFMS) phosphate mimetic that acts as a potent, reversible, competitive, and active-site directed inhibitor of protein tyrosine phosphatases (PTP; IC50 = 1.8, 2.5, 8.4, 13, 20, 6.4, and 6.7 µM for SHP-2, PTP1B, PTP-ε, PTP-Meg-2, PTP-ς, PTP-β, and PTP-µ, respectively).
An uncharged, 1,4-di-substituted, phenyl-linked, bis-trifluoromethylsulfonamido (TFMS) phosphate mimetic that acts as a potent, reversible, substrate competitive, active-site-directed inhibitor of protein tyrosine phosphatases (PTP). Reported to inhibit SHP-2 (IC50 = 1.8 µM), PTP1B (IC50 = 2.5 µM), PTP-ε (IC50 = 8.4 µM), PTP-Meg-2 (IC50 = 13 µM), PTP-ς (IC50 = 20 µM), PTP-β (IC50 = 6.4 µM), and PTP-µ (IC50 = 6.7 µM).
生化/生理作用
Cell permeable: no
Primary Target
SHP-2
SHP-2
Product competes with ATP.
Reversible: yes
Target IC50: 1.8, 2.5, 8.4, 13, 20, 6.4, and 6.7 µM for SHP-2, PTP1B, PTP-ε, PTP-Meg-2, PTP-σ, PTP-β, and PTP-µ, respectively
包装
Packaged under inert gas
警告
Toxicity: Standard Handling (A)
重悬
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
其他说明
Huang, P., et al. 2003. Bioorg. Med. Chem.11, 1835.
法律信息
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
WGK
WGK 1
闪点(°F)
Not applicable
闪点(°C)
Not applicable
D G Semaan et al.
Journal of ethnopharmacology, 203, 39-46 (2017-03-28)
Ethno-botanical information from diabetic patients in Cuba led to the identification of Allophylus cominia as a possible source of new drugs for the treatment of type 2 diabetes mellitus (T2-DM). Chemical characterization of the extracts from A. cominia was carried
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门